Janux Therapeutics Correlations
JANX Stock | USD 29.94 0.49 1.61% |
The current 90-days correlation between Janux Therapeutics and Mineralys Therapeutics, Common is 0.11 (i.e., Average diversification). The correlation of Janux Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Janux Therapeutics Correlation With Market
Weak diversification
The correlation between Janux Therapeutics and DJI is 0.31 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Janux Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Janux |
Moving together with Janux Stock
0.83 | CDIOW | Cardio Diagnostics | PairCorr |
0.84 | ELVN | Enliven Therapeutics | PairCorr |
0.85 | SCLX | Scilex Holding | PairCorr |
0.86 | ASMB | Assembly Biosciences Earnings Call This Week | PairCorr |
0.88 | CDIO | Cardio Diagnostics | PairCorr |
0.95 | CRNX | Crinetics Pharmaceuticals | PairCorr |
0.82 | MSFT | Microsoft | PairCorr |
Moving against Janux Stock
0.86 | WM | Waste Management | PairCorr |
0.84 | LUCD | Lucid Diagnostics | PairCorr |
0.82 | GE | GE Aerospace | PairCorr |
0.7 | PLX | Protalix Biotherapeutics | PairCorr |
0.41 | PG | Procter Gamble | PairCorr |
0.89 | JNJ | Johnson Johnson | PairCorr |
0.85 | T | ATT Inc Earnings Call Tomorrow | PairCorr |
0.84 | MMM | 3M Company | PairCorr |
0.78 | CVX | Chevron Corp | PairCorr |
0.72 | CSCO | Cisco Systems | PairCorr |
0.71 | IBM | International Business | PairCorr |
0.64 | XOM | Exxon Mobil Corp | PairCorr |
0.55 | INTC | Intel | PairCorr |
0.31 | DD | Dupont De Nemours | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Janux Stock performing well and Janux Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Janux Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
MLYS | 4.29 | 0.63 | 0.17 | (0.45) | 4.26 | 10.04 | 50.53 | |||
ELYM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
ANEB | 5.72 | 0.62 | 0.10 | 0.37 | 5.70 | 19.58 | 40.87 | |||
RZLT | 3.07 | (0.48) | 0.00 | (0.58) | 0.00 | 5.62 | 22.04 | |||
KROS | 2.63 | (0.73) | 0.00 | 9.16 | 0.00 | 4.41 | 19.64 | |||
FENC | 2.06 | 0.26 | 0.08 | 0.14 | 2.93 | 4.75 | 16.33 | |||
EWTX | 2.92 | (0.07) | 0.00 | (0.12) | 0.00 | 5.32 | 26.44 | |||
HRMY | 1.98 | 0.23 | 0.07 | 0.17 | 2.96 | 4.36 | 17.63 | |||
MOLN | 2.72 | (0.28) | 0.00 | (0.21) | 0.00 | 7.84 | 20.58 | |||
MNOV | 2.24 | (0.39) | 0.00 | (0.58) | 0.00 | 5.35 | 16.27 |
Janux Therapeutics Corporate Management
Brenda Vreeswyk | Head Resources | Profile | |
Zachariah DO | Chief Officer | Profile | |
Wayne MD | Chief Officer | Profile | |
Matt Whitmire | Vice Finance | Profile | |
Charles Winter | Manufacturing Chemistry | Profile | |
CFA CPA | Acting Officer | Profile | |
Andy Meyer | Chief Officer | Profile |